Statistics from Altmetric.com
Myeloid-derived suppressor cells (MDSC) represent an immune cell subset with profound immune suppressor function. Initially described in 1978 as natural suppressor cells, this cell type has gained significant attention in recent years not only among tumour immunologists but also among medical oncologists interested both in developing new immune-based antitumour strategies and trying to understand how conventional non-immunological therapies affect antitumour immune responses.1 MDSC represent a mixture of immature cell types that accumulate in tumour-bearing mice and patients with cancer. Tumour-derived factors block the maturation of myeloid cells at different stages, leading to accumulation of these cells in tumours, as well as in the periphery. At least two different subsets of MDSC have been described in mice and men: monocytic and polymorphonuclear granulocytic MDSC, which can be identified as CD14+HLA-DRlo/neg and linnegCD11b+HLA-DRneg in patients2 and as CD11b+Ly6G+ Ly6Clow or CD11b+Ly6Gneg Ly6Chi in mice.3
An accumulation of MDSC has been described in multiple models of pancreatic cancer. We have been able to demonstrate an accumulation of MDSC in mice with premalignant lesions.4 Similarly, an accumulation of MDSC, regulatory T cells and tumour-associated macrophages has been described in KC mice, …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.